Myosin Therapeutics, a Jupiter, FL-based biotechnology company developing novel therapies for cancer and neurological disorders, closed its second Seed funding round, raising over $3M to supplement investment from the National Institutes of Health.
The Seed was led by DeepWork Capital, Florida Opportunity Fund, and Mint12 Pharma, along with Dynagrow Capital, the private investment management affiliate of Fred Hassan, Mayo Clinic Ventures, and The Sontag Innovation Fund.
The company intends to use the funds to initiate multiple clinical trials this year, including a Phase 1b trial for MT-125 in glioblastoma patients.
Led by CEO Dr. Courtney Miller, Myosin Therapeutics is a biotechnology company spun out of The Herbert Wertheim UF Scripps Institute (formerly Scripps Research, Florida), which is focused on developing therapies for neuroscience and oncology indications using a platform that targets molecular nanomotor proteins.
Myosin Therapeutics is advancing its lead compound, MT-125, to treat glioblastoma, the most aggressive brain cancer with an average survival time of only 8 months. MT-125 targets a molecular nanomotor, blocking both tumor growth and invasion. The FDA granted orphan drug designation to MT-125 for malignant gliomas, underscoring its potential to improve outcomes for patients with this devastating disease.
The company is also progressing MT-110 for the treatment of methamphetamine use disorder (MUD), Millions worldwide suffer from MUD, yet no FDA-approved treatments currently exist. The latest funding, combined with NIH support, will allow MT-110 to enter Phase 1 clinical trials.
FinSMEs
03/03/2025